Try
ANI PHARMACEUTICALS INC
ANIPUnited States
110 filed reports · 608 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
110 reports · Jun 2014 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 369 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 61 | 373 | Jun 2014 to Jun 2026 |
| Quarterly · 10-QSEC EDGAR | 37 | 6,133 | Jun 2014 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 12 | 5,619 | Dec 2014 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 7, 2026 | 408 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 7, 2026 | 8 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 8, 2026 | 291 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 8, 2026 | 8 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 27, 2026 | 1,156 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 27, 2026 | 8 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Jan 12, 2026 | 6 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Nov 10, 2025 | 8 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 7, 2025 | 322 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Nov 7, 2025 | 10 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Sep 8, 2025 | 4 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Aug 8, 2025 | 8 | Open |
Financial data
608 concepts · 12,125 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial574 concepts · 10,745 facts · Dec 2012 to Jun 2026
- Cash and cash equivalents at carrying value68 · Dec 2012 to Jun 2026
- Amortization of intangible assets67 · Jun 2013 to Jun 2026
- Costs and expenses67 · Jun 2013 to Jun 2026
- Income tax expense benefit67 · Jun 2013 to Jun 2026
- Interest income expense nonoperating net67 · Jun 2013 to Jun 2026
- Net income loss67 · Jun 2013 to Jun 2026
- Net income loss available to common stockholders basic67 · Jun 2013 to Jun 2026
- Operating income loss67 · Jun 2013 to Jun 2026
- Other nonoperating income expense67 · Jun 2013 to Jun 2026
- Research and development expense67 · Jun 2013 to Jun 2026
- Revenue67 · Jun 2013 to Jun 2026
- Selling general and administrative expense67 · Jun 2013 to Jun 2026
- Net income loss available to common stockholders diluted66 · Sep 2013 to Jun 2026
- Share based compensation66 · Jun 2013 to Jun 2026
- Goodwill (US GAAP)65 · Jun 2013 to Jun 2026
- Increase decrease in accounts payable65 · Sep 2013 to Jun 2026
- Increase decrease in accounts receivable65 · Sep 2013 to Jun 2026
- Increase decrease in inventories65 · Sep 2013 to Jun 2026
- Increase decrease in prepaid expense65 · Sep 2013 to Jun 2026
- Net cash provided by used in financing activities65 · Sep 2013 to Jun 2026
- Payments to acquire property plant and equipment65 · Sep 2013 to Jun 2026
- Proceeds from stock options exercised65 · Sep 2013 to Jun 2026
- Stockholders equity (US GAAP)65 · Dec 2012 to Jun 2026
- Net cash provided by used in operating activities64 · Dec 2013 to Jun 2026
Segment19 concepts · 452 facts · Dec 2016 to Jun 2026
- Revenue91 · Dec 2016 to Jun 2026
- Operating Segments38 · Dec 2020 to Sep 2024
- Cost of goods and service excluding depreciation depletion and amortization28 · Dec 2022 to Jun 2026
- Depreciation and amortization28 · Dec 2022 to Jun 2026
- Interest income expense nonoperating net28 · Dec 2022 to Jun 2026
- Operating income loss28 · Dec 2022 to Jun 2026
- Other nonoperating income expense28 · Dec 2022 to Jun 2026
- Research and development expense28 · Dec 2022 to Jun 2026
- Selling general and administrative expense28 · Dec 2022 to Jun 2026
- Business combination contingent consideration arrangements change in amount of contingent consideration liability124 · Dec 2022 to Jun 2026
- Equity securities fv ni unrealized gain loss24 · Mar 2024 to Jun 2026
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest24 · Dec 2022 to Jun 2026
- Property, Plant & Equipment, Net18 · Sep 2018 to Mar 2020
- Gain loss on disposition of assets110 · Dec 2024 to Dec 2025
- Intangible asset impairment charge10 · Dec 2022 to Dec 2025
- Gain loss on sale of property plant equipment6 · Mar 2024 to Dec 2024
- Gains losses on extinguishment of debt4 · Dec 2024
- Restructuring and related cost incurred cost4 · Dec 2022 to Dec 2023
- Number of reporting units3 · Mar 2025 to Sep 2025
Product2 concepts · 428 facts · Jun 2013 to Jun 2026
- Revenue423 · Jun 2013 to Jun 2026
- Selling general and administrative expense5 · Dec 2019 to Dec 2023
Guidance11 concepts · 373 facts · Aug 2014 to Aug 2026
- Revenue Guidance124 · Aug 2014 to Aug 2026
- EPS (Diluted) Guidance118 · Aug 2014 to Aug 2026
- Effective Tax Rate Guidance52 · Aug 2014 to Aug 2026
- Gross Margin Guidance46 · Mar 2023 to Aug 2026
- Revenue Growth Guidance14 · Nov 2024 to Nov 2025
- EPS (Diluted) Guidance (Adjusted (non-GAAP))8 · Feb 2016 to May 2025
- Capital Expenditures Guidance3 · Mar 2017 to Feb 2018
- Effective Tax Rate Guidance (Adjusted (non-GAAP))2 · May 2025
- EPS (Diluted) Growth Guidance2 · Nov 2025
- EPS (Diluted) Growth Guidance (Adjusted (non-GAAP))2 · May 2025
- Gross Margin Guidance (Adjusted (non-GAAP))2 · May 2025
Geography2 concepts · 127 facts · Dec 2018 to Dec 2025
- Revenue66 · Dec 2018 to Dec 2025
- Property, Plant & Equipment, Net61 · Dec 2019 to Dec 2025
Segments
1,007 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments8 members · 452 facts
- Rare Disease And Brands168 · Dec 2022 to Jun 2026
- Generics And Other165 · Dec 2022 to Jun 2026
- Generics Established Brands And Other38 · Dec 2020 to Sep 2024
- Rare Disease33 · Dec 2020 to Sep 2024
- Canada15 · Dec 2016 to Mar 2020
- United States15 · Dec 2016 to Mar 2020
- Canada9 · Sep 2018 to Mar 2020
- United states9 · Sep 2018 to Mar 2020
Product or servicesrt:ProductOrServiceAxis22 members · 392 facts
- Sales Of Generic Pharmaceutical Products47 · Dec 2016 to Jun 2026
- Unapproved Products47 · Dec 2016 to Jun 2026
- Sales Of Branded Pharmaceutical Products31 · Dec 2016 to Dec 2023
- Other Revenues30 · Dec 2016 to Dec 2022
- Sales Of Contract Manufactured Products30 · Dec 2016 to Dec 2022
- Product Development Services29 · Dec 2016 to Dec 2022
- Royalties From Licensing Agreements29 · Dec 2016 to Dec 2022
- Sales Of Cortrophin Gel16 · Dec 2022 to Jun 2026
- Sales Of ILUVIEN And YUTIQ16 · Dec 2022 to Jun 2026
- Total Sales Of Rare Disease Pharmaceutical Products16 · Dec 2022 to Jun 2026
- Sales Of Established Brands14 · Dec 2022 to Jun 2026
- Total Sales Of Generics And Other14 · Dec 2022 to Jun 2026
- Total Sales Of Rare Disease And Brands14 · Dec 2022 to Jun 2026
- Sales Of Rare Disease Pharmaceutical Products13 · Dec 2021 to Jun 2024
- Sales Of Royalties And Other Pharmaceutical Services12 · Dec 2022 to Dec 2025
- Performance Obligation From Prior Period9 · Mar 2018 to Mar 2020
- Sales Of Branded Royalties And Other Pharmaceutical Services8 · Mar 2022 to Jun 2024
- Cortrophin Gel5 · Dec 2019 to Dec 2023
- Sales Of Established Brand Royalties And Other Revenues4 · Mar 2025 to Jun 2026
- Sales Of Generic Other Revenues4 · Mar 2025 to Jun 2026
- Sales Of Established Brand Products Royalties And Other Pharmaceutical Services2 · Sep 2023 to Sep 2024
- Total Sales Of Generic And Established Brand Pharmaceutical Products Royalties And Other Pharmaceuticals Services2 · Sep 2023 to Sep 2024
Statement geographical7 members · 127 facts
- US31 · Dec 2018 to Dec 2025
- CA27 · Dec 2018 to Jun 2024
- Us26 · Dec 2019 to Dec 2025
- Ca16 · Dec 2019 to Dec 2022
- In14 · Dec 2021 to Jun 2024
- Non Us8 · Dec 2022 to Dec 2025
- Non us5 · Dec 2023 to Dec 2025
Product or serviceus-gaap:ProductOrServiceAxis7 members · 36 facts
- Unapproved Products25 · Jun 2013 to Mar 2018
- Other Revenues2 · Mar 2017 to Mar 2018
- Royalties On Sales Of Pharmaceutical Products2 · Mar 2017 to Mar 2018
- Sales Of Branded Pharmaceutical Products2 · Mar 2017 to Mar 2018
- Sales Of Contract Manufactured Products2 · Mar 2017 to Mar 2018
- Sales Of Generic Pharmaceutical Products2 · Mar 2017 to Mar 2018
- Performance Obligation From Prior Period1 · Mar 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.